Mylan has formed a partnership with Atomo Diagnostics to expand access to HIV self-testing products in developing and under-developed countries.

Mylan has gained exclusive rights to commercialise Atomo Diagnostics’ in-vitro HIV rapid diagnostic test products in more than 100 countries in Africa, Asia, the Middle East, and Latin America through the agreement.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Based in the US, Mylan is a pharmaceutical company engaged in the development of over-the-counter (OTC) drugs, while Atomo Diagnostics is a medical device company engaged in the development of in-vitro diagnostic products.

The partnership will enable the two companies to provide all-in-one test devices, designed to improve functionality and ease-of-use when compared to current multi-component diagnostic tests.

Daiichi Sankyo has signed a clinical research collaboration agreement with Merck’s subsidiary to evaluate its investigational HER2 targeting antibody drug conjugate DS-8201 and Keytruda® (pembrolizumab) in HER2 expressing advanced/metastatic breast and HER2 mutant non-small cell lung cancers.

DS-8201 is designed to target and deliver chemotherapy inside cancer cells, while Keytruda® is the first anti-PD-1 (programmed death receptor-1) therapy indicated for the treatment of unresectable or metastatic melanoma.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
“Takeda Pharmaceutical has signed a commercialisation agreement with Molecular Templates to develop protein-based oncology therapies for cancer treatment.”

Daiichi Sankyo will conduct a two-part, multi-centre, open-label study to evaluate the safety and efficacy of DS-8201 and Keytruda® in cancer patients across the US and Europe.

Based in Japan, Daiichi Sankyo is a pharmaceutical company engaged in the development of therapies in the areas of hypertension and diabetes, while Merck is a healthcare solutions provider based in the US.

Takeda Pharmaceutical has signed a commercialisation agreement with Molecular Templates to develop protein-based oncology therapies for cancer treatment.

The two companies will focus on the development of CD38-targeted engineered toxin bodies (ETBs) for the treatment of patients suffering from multiple myeloma.

Molecular Templates will receive an upfront payment of $30m from Takeda and up to $632.5m in milestone payments upon exercising its co-development option, as per the the agreement.

Based in Japan, Takeda is engaged in the development of pharmaceuticals for metabolic and cardiovascular diseases, while Molecular Templates is a US-based clinical-stage biopharmaceutical company engaged in the development of therapeutics for cancer.